Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study by Xu, Jianming, Prof, Shen, Lin, Prof, Zhou, Zhiwei, Prof, Li, Jie, Prof, Bai, Chunmei, Prof, Chi, Yihebali, Prof, Li, Zhiping, Prof, Xu, Nong, Prof, Li, Enxiao, Prof, Liu, Tianshu, Prof, Bai, Yuxian, Prof, Yuan, Ying, Prof, Li, Xingya, Prof, Wang, Xiuwen, Prof, Chen, Jia, Prof, Ying, Jieer, Prof, Yu, Xianjun, Prof, Qin, Shukui, Prof, Yuan, Xianglin, Prof, Zhang, Tao, Prof, Deng, Yanhong, Prof, Xiu, Dianrong, Prof, Cheng, Ying, Prof, Tao, Min, Prof, Jia, Ru, MD, Wang, Wei, MD, Li, Jing, MD, Fan, Songhua, MD, Peng, Mengye, PhD, Su, Weiguo, PhD

Get full text

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study by Xu, Jianming, Prof, Shen, Lin, Prof, Bai, Chunmei, Prof, Wang, Wei, MD, Li, Jie, Prof, Yu, Xianjun, Prof, Li, Zhiping, Prof, Li, Enxiao, Prof, Yuan, Xianglin, Prof, Chi, Yihebali, Prof, Yin, Yongmei, Prof, Lou, Wenhui, Prof, Xu, Nong, Prof, Bai, Yuxian, Prof, Zhang, Tao, Prof, Xiu, Dianrong, Prof, Wang, Xiuwen, Prof, Yuan, Ying, Prof, Chen, Jia, Prof, Qin, Shukui, Prof, Jia, Ru, MD, Lu, Ming, MD, Cheng, Yuejuan, MD, Zhou, Zhiwei, Prof, Li, Jing, MD, He, James, MD, Su, Weiguo, PhD

Get full text

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, plac... by Wang, Jie, Prof, Zhou, Caicun, Prof, Yao, Wenxiu, Prof, Wang, Qiming, Prof, Min, Xuhong, BS, Chen, Gongyan, Prof, Xu, Xingxiang, Prof, Li, Xingya, Prof, Xu, Fei, Prof, Fang, Yong, Prof, Yang, Runxiang, Prof, Yu, Guohua, Prof, Gong, Youling, Prof, Zhao, Jun, Prof, Fan, Yun, Prof, Liu, Quan, Prof, Cao, Lejie, Prof, Yao, Yu, Prof, Liu, Yunpeng, Prof, Li, Xiaoling, Prof, Wu, Jingxun, Prof, He, Zhiyong, Prof, Lu, Kaihua, Prof, Jiang, Liyan, Prof, Hu, Chengping, Prof, Zhao, Wenhua, MD, Zhang, Ben, Ms, Shi, Wei, MD, Zhang, Xiaojing, MD, Cheng, Ying, Prof

Get full text

Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study by Pan, Jing, MD, Tang, Kaiting, BS, Luo, Yuechen, PhD, Seery, Samuel, PhD, Tan, Yue, BS, Deng, Biping, MS, Liu, Feng, MS, Xu, Xiuwen, MD, Ling, Zhuojun, MD, Song, Weiliang, MD, Xu, Jinlong, MD, Duan, Jiajia, MD, Wang, Zelin, MD, Li, Chunyu, MD, Wang, Kai, MD, Zhang, Yibing, BS, Yu, Xinjian, MD, Zheng, Qinlong, MD, Zhao, Liping, BS, Zhang, Jiecheng, BS, Chang, Alex H, PhD, Feng, Xiaoming, Prof

Get full text

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment... by Harbeck, Nadia, Prof, Huang, Chiun-Sheng, Prof, Hurvitz, Sara, MD, Yeh, Dah-Cherng, MD, Shao, Zhimin, Prof, Im, Seock-Ah, Prof, Jung, Kyung Hae, Prof, Shen, Kunwei, MD, Ro, Jungsil, MD, Jassem, Jacek, Prof, Zhang, Qingyuan, Prof, Im, Young-Hyuck, MD, Wojtukiewicz, Marek, Prof, Sun, Qiang, MD, Chen, Shin-Cheh, Prof, Goeldner, Rainer-Georg, PhD, Uttenreuther-Fischer, Martina, MD, Xu, Binghe, Prof, Piccart-Gebhart, Martine, MD

Get full text